Colorectal Cancer

Tanios S. Bekaii-Saab, MD, discusses sequencing approaches in metastatic pancreatic cancer and colorectal cancer.

Fulzerasib monotherapy was safe and active in KRAS G12C–mutated metastatic colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses efforts to shift emerging targeted therapies into earlier treatment lines for patients with mCRC.

Botensilimab plus balstilimab displayed durable responses in refractory CRC, including in heavily pretreated patient subsets.

Evelyn Y. Wong, MD, discusses an analysis of a multiracial Asian cohort on the incidence of early‑onset colorectal cancer.

Evelyn Y.T. Wong, MD, discusses survival outcomes and molecular characteristics of patients with early-onset colorectal cancer from a cohort in Singapore.

Neoadjuvant pembrolizumab could represent an avenue for organ preservation in nonmetastatic, unresectable, dMMR colorectal cancer.

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.

Frank A. Sinicrope, MD, discuses the implications of data with atezolizumab plus adjuvant mFOLFOX6 for the management of stage III, dMMR colon cancer.

Read a recap of the episodes of OncLive On Air that debuted in July 2025.

Onvansertib plus SOC generated responses with a tolerable safety profile in patients with previously untreated RAS-mutated metastatic colorectal cancer.

Panelists discuss how important clinical pearls include early genomic profiling, emphasizing lifestyle modifications like exercise programs that can reduce recurrence by 7%, and using olanzapine as the most effective antiemetic for delayed chemotherapy-related nausea.

Panelists discuss how immunotherapy generally provides better quality of life compared to traditional chemotherapy, particularly noting that microsatellite instability-high patients on immune checkpoint inhibitors report significantly better experiences than those on FOLFOX regimens.

Panelists discuss how they assess quality of life in clinical practice by asking simple questions like “What do you do for fun?” and “How was your week?” rather than relying solely on formal quality of life questionnaires.

Panelists discuss how they’re excited about future combination therapies, particularly TAS-102 with fruquintinib and novel immunotherapy approaches targeting patients with liver metastases who are typically checkpoint inhibitor refractory.

Sharlene Gill, MD, MPH, MBA, FRCPC, highlights the importance of considering patients’ concerns ahead of treatment decision-making for advanced CRC.

Cathy Eng, MD, FACP, FASCO, discusses real-world data on KRAS G12C–mutated mCRC, highlighting its potential prognostic impact in the frontline setting.

Cathy Eng, MD, FACP, FASCO, discusses a real-world study of the effect of KRAS G12C mutations on outcomes in patients with metastatic colorectal cancer.

Panelists discuss how they approach rechallenge with chemotherapy, considering it primarily in patients who never truly progressed on oxaliplatin-based therapy or those who might benefit from EGFR antibody reintroduction after a drug holiday.

Panelists discuss how they manage fruquintinib dosing by starting at lower doses (3 to 4 mg) in patients with poor performance status or frailty, then titrating up as tolerated rather than starting at the full 5-mg dose.

Regorafenib plus trifluridine/tipiracil was active in patients with pretreated metastatic colorectal cancer.

Frank A. Sinicrope, MD, discuses the efficacy and safety of atezolizumab plus mFOLFOX6 in patients with stage III dMMR colon cancer

Rocío García-Carbonero, MD, discusses safety challenges in third-line mCRC and the role of molecular testing in aggressive GI neuroendocrine tumors.

Rocío García-Carbonero, MD, PhD, discusses findings from a subgroup analysis of FRESCO-2 with fruquintinib in refractory mCRC.

Panelists discuss how they modify dosing schedules for TAS-102 (trifluridine/tipiracil), with some preferring every-other-week dosing instead of the standard 2-weeks-on schedule to reduce neutropenia and improve tolerability.